ArticleAdvances in therapy2026

Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors.

Philip J Mease et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.